Simulations Plus (NASDAQ:SLP) Issues FY 2025 Earnings Guidance

Simulations Plus (NASDAQ:SLP) issued an update on its FY 2025 earnings guidance on Thursday morning. The company provided earnings per share (EPS) guidance of 1.070-1.200 for the period, compared to the consensus estimate of 1.090. The company issued revenue guidance of $90.0 million-$93.0 million, compared to the consensus revenue estimate of $90.4 million. Simulations Plus also updated its FY25 guidance to $1.07-1.20 EPS.

Wall Street Analysts Forecast Growth

SLP has been the topic of several recent research reports. William Blair reaffirmed an “outperform” rating on shares of Simulations Plus in a research note on Wednesday, January 8th. KeyCorp lifted their price objective on Simulations Plus from $35.00 to $37.00 and gave the company an “overweight” rating in a report on Friday, January 24th. One research analyst has rated the stock with a sell rating, one has issued a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $49.40.

Simulations Plus Stock Down 3.8 %

SLP traded down $0.95 during trading on Thursday, hitting $23.82. 353,320 shares of the company’s stock were exchanged, compared to its average volume of 175,221. The stock has a market cap of $478.59 million, a P/E ratio of 59.55 and a beta of 0.89. The business’s 50 day moving average is $30.38 and its two-hundred day moving average is $30.38. Simulations Plus has a fifty-two week low of $23.00 and a fifty-two week high of $51.22.

Simulations Plus (NASDAQ:SLP) last issued its quarterly earnings data on Thursday, April 3rd. The technology company reported $0.31 earnings per share for the quarter, beating the consensus estimate of $0.25 by $0.06. Simulations Plus had a return on equity of 6.84% and a net margin of 10.97%. The business had revenue of $22.43 million for the quarter, compared to analysts’ expectations of $21.93 million. During the same period last year, the business earned $0.20 EPS. The business’s revenue was up 22.5% on a year-over-year basis. On average, sell-side analysts forecast that Simulations Plus will post 1.09 earnings per share for the current year.

Insider Activity

In related news, Director Walter S. Woltosz sold 20,000 shares of the company’s stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $33.91, for a total value of $678,200.00. Following the completion of the transaction, the director now directly owns 3,402,584 shares in the company, valued at approximately $115,381,623.44. The trade was a 0.58 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 19.40% of the company’s stock.

Simulations Plus Company Profile

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.